Effectiveness Analysis of the Combination of Sintilimab and Albumin Bound Paclitaxel in Patients with Advanced Esophageal Cancer
Objective To analyze the effect of combined treatment with sintilimab and albumin bound paclitaxel(nab-PTX)in patients with advanced esophageal cancer.Methods 150 cases of advanced esophageal cancer admitted to Binzhou Central Hospital from August 2020 to July 2023 were randomly selected as the study objects and divided into two groups with reference to the random number table method.The patients in the control group(n=75)were treated with nab-PTX combined with cisplatin chemotherapy,and the patients in the study group(n=75)were treated with a combination of sintilimab in addition to the control group.The clinical efficacy,tumor markers carcinoembryonic anti-gen,cytokeratin 19 fragment,squamous cell carcinoma antigen levels,and adverse reactions were compared between the two groups.Results The objective remission rate(62.67%)and disease control rate(89.33%)of the study group were higher than those of the control group(42.67%and 76.00%),and the differences were statistically significant(χ2 =6.017,4.653,both P<0.05).After treatment,compared with the control group,the study group had lower levels of car-cinoembryonic antigen,cytokeratin 19 fragment,and squamous cell carcinoma antigen,and the differences were statis-tically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions such as gastrointestinal reactions,bone marrow suppression,fever,liver function abnormality and hypothyroidism be-tween the two groups(all P>0.05).Conclusion The combined treatment of advanced esophageal cancer patients with sintilimab and nab-PTX can effectively improve the disease control rate and objective remission rate,regulate the ex-pression of tumor markers,with ideal safety.
SintilimabAlbumin bound paclitaxelAdvanced esophageal cancer
NETL
NSTL
万方数据
维普
